نتایج جستجو برای: inclusion body myositis

تعداد نتایج: 845562  

Journal: :Journal of Internal Medicine 2016

2014
A.R. Santos M.T. Neves B. Gualano G.C. Laurentino A.H. Lancha C. Ugrinowitsch F.R. Lima M.S. Aoki

UNLABELLED Inclusion body myositis is a rare idiopathic inflammatory myopathy that produces extreme muscle weakness. Blood flow restricted resistance training has been shown to improve muscle strength and muscle hypertrophy in inclusion body myositis. OBJECTIVE The aim of this study was to evaluate the effects of a resistance training programme on the expression of genes related to myostatin ...

Journal: :Current rheumatology reports 2010
Steven A Greenberg

Inclusion body myositis is a progressive disease of the skeletal muscle. Here, specific theories of its pathogenesis are reviewed and general considerations pertaining to modeling of this disease discussed. Understanding of inclusion body myositis disease mechanism remains extremely poor. Current published animal models do not represent the disease. Future studies need to consider the critical ...

Journal: :anesthesiology and pain medicine 0
dominik t steck department of anesthesiology, medical college of wisconsin, milwaukee, wisconsin, usa christine choi department of anesthesiology, medical college of wisconsin, milwaukee, wisconsin, usa suneeta gollapudy department of anesthesiology, medical college of wisconsin, milwaukee, wisconsin, usa paul s pagel anesthesia service, clement j zablocki veterans affairs medical center, milwaukee, wisconsin, usa; anesthesia service, clement j zablocki veterans affairs medical center, milwaukee, wisconsin, usa. tel: +414-3842000, fax: +414-9025479

conclusions in summary, there is a lack of consensus about the use of neuromuscular blockers in patients with ibm. the authors avoided these drugs and were able to easily secure the patient’s airway and maintain adequate muscle relaxation using a balanced sevoflurane-remifentanil anesthetic. clinical trials are necessary to define the pharmacology of neuromuscular blockers in patients with ibm ...

2017
J B Lilleker A Rietveld S R Pye K Mariampillai O Benveniste M T J Peeters J A L Miller M G Hanna P M Machado M J Parton K R Gheorghe U A Badrising I E Lundberg S Sacconi M K Herbert N J McHugh B R F Lecky C Brierley D Hilton-Jones J A Lamb M E Roberts R G Cooper C G J Saris G J M Pruijn H Chinoy B G M van Engelen

OBJECTIVES Autoantibodies directed against cytosolic 5'-nucleotidase 1A have been identified in many patients with inclusion body myositis. This retrospective study investigated the association between anticytosolic 5'-nucleotidase 1A antibody status and clinical, serological and histopathological features to explore the utility of this antibody to identify inclusion body myositis subgroups and...

Journal: :The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 1989
M J Danon M Friedman

A 68-year-old man known to have inclusion body myositis underwent a cricopharyngeal myotomy in an attempt to improve his progressive dysphagia. Morphological studies from tissues obtained during this procedure showed the diagnostic features typical of this chronic inflammatory myopathy. To our knowledge this is the first pathological demonstration of inclusion body myositis involving the pharyn...

Journal: :Annals of the Rheumatic Diseases 2023

Background Within the group of inflammatory myopathies, Inclusion-Body Myositis (IBM) is a distinct pathology with clinical and histological features very different from other entities. In literature, an association between primary Sjögren’s syndrome (pSS) IBM has been previously reported. Objectives The aim our study was to compare infiltrates associated or not pSS and, among patients pSS, mus...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید